Sommaire

Numéro précédent | Numéro suivant

• • ·Introduction

    Page :1A

    Gustav Schonfeld, James Shepherd

    
• • ·Lipid risk factors and the regression of atherosclerosis

    Page :3A

    Antonio M. Gotto

    Résumé Résumé
• • ·Clustering of cardiovascular risk factors: Targeting high-risk individuals

    Page :8A

    Jacques Genest, Jeffrey S. Cohn

    Résumé Résumé
• • ·Pathogenesis of atherosclerosisand the role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

    Page :21A

    Alberto Corsini, Marco Raiteri, Maurizio R. Soma, Franco Bernini, Remo Fumagalli, Rodolfo Paoletti

    Résumé Résumé
• • ·Lack of interaction between fluvastatin andoral nypoylycemie agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus

    Page :29A

    Silke Appel, Theres Rüfenacht, Gaetana Kalafsky, Wolfgang Tetzloff, Zoltan Kallay, Gerhart Hitzenberger, Klaus Kutz

    
• • ·Clinical efficacy of fluvastatin for hyperlipidemia in Japanese patients

    Page :33A

    Tamio Teramoto, Yuichiro Goto, Kiyoshi Kurokawa, Haruo Nakamura, Sho Yoshida, Yasushi Saito, Noriaki Nakaya, Hiroshige Itakura, Fumimaro Takaku, Nobuhiro Yamada, Yoshiya Hata, Fumio Kuzuya, Hiroshi Mabuchi, Toru Kita, Seiichiro Tarui, Yuji Matsuzawa, Akira Yamamoto, Motoo Tsushima, Goro Kajiyama, Kikuo Arakawa, Tadao Ishioka

    Résumé Résumé
• • ·Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coeezyme a reduefase inhibitor

    Page :37A

    James H. Zavoral, Betty Jo Haggerty, Andrea G. Winick, Scott D. Bergmann, FLUENT Study Group

    Résumé Résumé
• • ·Long-term efficacy with fluvastatinas monotherapy and combined with cholestyramine (A 156-week multicenter study)

    Page :41A

    Bernard Jacotot, Jan D. Banga, Roland Waite, Tim K. Peters, French-Dutch Fluvastatin Study Group

    Résumé Résumé
• • ·Clinical efficacy of fluvastatin in thelong-term treatment of familial hypercholesterolemia

    Page :47A

    Junii Koizumi, Tatsuo Haraki, Kunirnasa Yagi, Akihiro Inazu, Kouii Kalinami, Susurnu Miyamoto, Kosei Ueda, Masayuki Ohta, Tadayoshi Takegoshi, Mitsuaki Takeda, Yoshihide Uno, Hiroshi Mabuchi, Ryoyu Takeda

    Résumé Résumé
• • ·Effets of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia

    Page :51A

    Massimo Milani, Claudio Cimminiello, Barbara Merlo, Marco Lorena, Guido Arpaia, Guiseppe Bonfardeci

    Résumé Résumé
• • ·Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia

    Page :54A

    Bernard Jacotot, Renée Benghozi, Pascal Pfister, David Holmes, French Fluvastatin Study Group

    Résumé Résumé
• • ·Open-label study to assess the efficacy, safe, and tolerability of fluvastatin versus bezafibrate for hypercholesterolemia

    Page :57A

    Guillermo Fanghänel, Jorge Espinosa, David Olivares, Leticia Sánchez, Miguel Morales, Lourdes Martínez, Gabriela Maclas, Eulalia Valdés, Gustavo Hernández

    Résumé Résumé
• • ·Outcome monitoring of fluvastatin in a Department of Veterans Affairs Lipid Clinic

    Page :62A

    Kenneth A. Kellick, Kathleen Burns, Elizabeth McAndrew, Evelyn Haberl, Nancy Hook, Avery Ellis

    Résumé Résumé
• • ·Changes in plasmaapolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine

    Page :65A

    Jean-Marie Bard, Leiv Ose, Egil Hagen, Patrick Duriez, Pascal Pfister, Jean-Charles Fruchart, Jean Dallongeville, European Fluvastatin Study Group

    Résumé Résumé
• • ·Fluvastatin in severe hypercholesterolemia:Analysis of a clinical trial database

    Page :71A

    Tim K. Peters

    Résumé Résumé
• • ·High-dose fluvastatin and bezafibratecombination treatment for heterozygous familial hypercholesterolemia

    Page :76A

    Osnat Eliav, Daniel Schurr, Pascal Pfister, Yechiel Friedlander, Eran Leitersdorf

    Résumé Résumé
• • ·Pharmacokinetics of the combination of fluvastatin and gemfibrozil

    Page :80A

    J. David Spence, Claudio E. Munoz, Lisa Hendricks, Lilian Latchinian, Henry E. Khouri

    Résumé Résumé
• • ·Efficacy and safety of triple therapy(fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia

    Page :84A

    Eran Leitersdorf, Eleonora N. Muratti, Osnat Eliav, Tim K. Peters

    Résumé Résumé
• • ·Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin

    Page :89A

    Jan W.A. Smit, Herman J.A. Wijnne, Fred Schobben, Ad Sitsen, Tjerk W.A. de Bruin, D. Willem Erkelens

    Résumé Résumé
• • ·Fluvastatin for dyslipoproteinemia,with or without concomitant chronic renal insufficiency

    Page :97A

    Caroline J. Lintott, Russell S. Scott, Janice M. Bremer, Brett I. Shand

    Résumé Résumé
• • ·Effect of fluvastatin for safely loweringatherogenic lipids in renal transplant patients receiving cyclosporine

    Page :102A

    Hallvard Holdaas, Anders Hartmann, Jean Stenstrøm, Ketil J. Dahl, Marianne Borge, Pascal Pfister

    Résumé Résumé
• • ·A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine

    Page :107A

    Ronald B. Goldberg, David Roth

    Résumé Résumé
• • ·Effects of fluvastatin on humanbiliary lipids

    Page :110A

    Susumu Tazuma, Tosihide Ohya, Toshiyuki Mizuno, Itsuo Takizawa, Toshiroh Kunita, Kohki Takata, Kozo Hayashi, Fumiaki Hino, Hironori Tokumo, Tetsuhiko Watanabe, Harutoshi Sasaki, Goro Kajiyama

    Résumé Résumé
• • ·Effects of flwastatin on growth of porcine and human vascular smooth muscle cells in vitro

    Page :114A

    Gerhard Rogler, Karl J. Lackner, Gerd Schmitz

    Résumé Résumé
• • ·Is endothelial dysfunction reversible?

    Page :117A

    Roland E. Schmieder, Hans P. Schobel

    Résumé Résumé
• • ·Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease

    Page :122A

    Hermann W. Eichstädt, Herbert Eskötter, Ingo Hoffmann, Holger W. Amthauer, Gottfried Weidinger

    Résumé Résumé
• • ·Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage

    Page :126A

    Jan W.A. Smit, Gerard H. Jansen, Tjerk W.A. de Bruin, D. Willem Erkelens

    Résumé Résumé
• • ·Effect of fluvastatin on intermediatedensity Lipoprotein (remnants) and other lipoprotein levels in hypercholestarolemia

    Page :129A

    Frances E. Broyles, Carolyn E. Walden, Donald B. Hunninghake, Deborah Hill-Williams, Robert H. Knopp

    Résumé Résumé
• • ·Effects of fluvastatin on lipid profile andapolipoproteins in Chinese patients with hypercholesterolemia

    Page :136A

    Brian Tomlinson, Tony W.L. Mak, Jing Y.Y. Tsui, Jean Woo, Chi C. Shek, Julian A.J.H. Critchley, John R.L. Masarei

    Résumé Résumé
• • ·Health and economic issues in theprevention of coronary artery disease

    Page :140A

    Thomas Hogan